MUTATIONS IN CHOLESTERYL ESTER TRANSFER PROTEIN AND CARDIOVASCULAR-DISEASE RISK

被引：0
|
作者：
SHARP, DS
JONG, SB
GROVE, JS
YANO, K
BURCHFIEL, CM
RODRIGUEZ, BL
CURB, JD
JIANG, XC
TALL, AR
机构：
[1] COLUMBIA UNIV,NEW YORK,NY 10027
[2] HONOLULU HEART PROGRAM,HONOLULU,HI
来源：
CIRCULATION | 1995年 / 91卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：924 / 924
页数：1
相关论文
共 50 条
  • [1] The Yin and Yang of Cholesteryl Ester Transfer Protein in Cardiovascular Disease
    Shah, Prediman K.
    CIRCULATION, 2009, 120 (24) : 2408 - 2410
  • [2] Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk
    Barter, Philip J.
    Rye, Kerry-Anne
    JOURNAL OF LIPID RESEARCH, 2012, 53 (09) : 1755 - 1766
  • [3] - POINT - The Relationship between Cholesteryl Ester Transfer Protein and Cardiovascular Risk
    Barter, Philip J.
    CLINICAL CHEMISTRY, 2010, 56 (10) : 1547 - 1549
  • [4] Application of Genetic Epidemiology to CETP (Cholesteryl Ester Transfer Protein) Concentration and Risk of Cardiovascular Disease
    Merriman, Tony R.
    CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2018, 11 (05):
  • [5] Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease
    Barter, PJ
    Kastelein, JJP
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (03) : 492 - 499
  • [6] Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease
    Amand F. Schmidt
    Nicholas B. Hunt
    Maria Gordillo-Marañón
    Pimphen Charoen
    Fotios Drenos
    Mika Kivimaki
    Deborah A. Lawlor
    Claudia Giambartolomei
    Olia Papacosta
    Nishi Chaturvedi
    Joshua C. Bis
    Christopher J. O’Donnell
    Goya Wannamethee
    Andrew Wong
    Jackie F. Price
    Alun D. Hughes
    Tom R. Gaunt
    Nora Franceschini
    Dennis O. Mook-Kanamori
    Magdalena Zwierzyna
    Reecha Sofat
    Aroon D. Hingorani
    Chris Finan
    Nature Communications, 12
  • [7] Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease
    Schmidt, Amand F.
    Hunt, Nicholas B.
    Gordillo-Maranon, Maria
    Charoen, Pimphen
    Drenos, Fotios
    Kivimaki, Mika
    Lawlor, Deborah A.
    Giambartolomei, Claudia
    Papacosta, Olia
    Chaturvedi, Nishi
    Bis, Joshua C.
    O'Donnell, Christopher J.
    Wannamethee, Goya
    Wong, Andrew
    Price, Jackie F.
    Hughes, Alun D.
    Gaunt, Tom R.
    Franceschini, Nora
    Mook-Kanamori, Dennis O.
    Zwierzyna, Magdalena
    Sofat, Reecha
    Hingorani, Aroon D.
    Finan, Chris
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [8] Elevated plasma cholesteryl ester transfer but not cholesteryl ester transfer protein mass predicts incident cardiovascular disease independently of plasma lipids
    Kappelle, P. J. W. H.
    Perton, F.
    Hillege, H. L.
    Dallinga-Thie, G. M.
    Dullaart, R. P. F.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2012, 42 : 52 - 52
  • [9] The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease
    Mehta, Nehal
    Dangas, Katerina
    Ditmarsch, Marc
    Rensen, Patrick C. N.
    Dicklin, Mary R.
    Kastelein, John J. P.
    PHARMACOLOGICAL RESEARCH, 2023, 197
  • [10] The Promise of Cholesteryl Ester Transfer Protein (CETP) Inhibition in the Treatment of Cardiovascular Disease
    Bochem, A. E.
    Kuivenhoven, A.
    Stroes, E. S. G.
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (17) : 3143 - 3149
12345